M. Belvisi (London, United Kingdom), G. Brusselle (Ghent, Belgium)
Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD R. Dal Negro, M. Visconti, F. Trevisan, S. Bertacco, C. Micheletto (Bussolengo, VR, Italy)
|   |
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients P. Kuna, I. Vinkler, T. Overend, S. Snape, R. Tansley (Lodz, Poland; Nyiregyhaza, Hungary; Horsham, Saffron Walden, United Kingdom)
|   |
Cross sectional analysis of inflammatory mediators in exhaled breath condensate from COPD patients and healthy smoking controls I. Kilty, D. Anderson, R. Hidi, M. Bennetts, O. Beckonert, J. Barr, A. Deans, P. Phillips, W. MacNee (Sandwich, Edinburgh, United Kingdom)
|   |
Mitogen-activated protein kinase (MAPK) is involved in tight junction (TJ) disruption in a human bronchial epithelial cell line (Beas-2B) induced by cigarette smoke (CS) L. Petecchia, F. Sabatini, L. Varesio, G. A. Rossi (Genoa, Italy)
|   |
The effect of salmeterol/fluticasone propionate (SFC) on bronchial mucosal neutrophils and IL-8 gene expression in COPD Y. Qiu, N. Barnes, I. Pavord, J. Zhu, M. Johnson, N. Thomson, P. Jeffery (London, Leicester, Greenford, Middlesex, Glasgow, United Kingdom)
|  |
C-reactive protein levels and the risk of COPD in a general population: the Rotterdam study Y. M. T. A. van Durme, K. M. C. Verhamme, G. R. Van Pottelberge, A. Hofman, G. F. Joos, B. H. Stricker, G. G. Brusselle (Ghent, Belgium; Rotterdam, Netherlands)
|   |
The effect of tiotropium (TIO) on levels of desmosine and isodesmosine (D/I) in urine, plasma and sputum in COPD S. Ma, L. Yong Y, G. M. Turino (New York, NY, United States Of America)
|   |
COPD and oxidative stress: NAC‘s (n-acetylcysteine) effects G. Schiraldi, F. Blasi, S. Della Patrona, R. Accinni, C. Della Noce, T. Cappelletti, M. Bianchi, L. Allegra (Milan, Italy)
|   |
CREB signaling and chromatin remodeling during corticosteroid and theophylline therapy of COPD R. Mroz, A. Holownia, E. Drost, E. Chyczewska, J. Braszko, J. Noparlik, K. Donaldson, W. MacNee (Bialystok, Poland; Edinburgh, United Kingdom)
|  |
Heart rate responses to exercise with tiotropium in patients with COPD D. O‘Donnell, K. Webb, F. Maltais, A. Hamilton, I. Leimer, S. Kesten (Kingston, Laval, Canada; Burlington, Ridgefield, Ingelheim, Germany)
|  |
Factors associated with mortality in the TORCH trial in COPD P. Calverley, B. Celli, J. Anderson, G. Ferguson, C. Jenkins, P. Jones, J. Yates, J. Vestbo (Liverpool, Greenford, London, Manchester, United Kingdom; Boston, MA, Livonia, MI, RTP, NC, United States Of America; Sydney, Australia)
|  |
Effect of exacerbation history on response to treatment in the TORCH trial C. R. Jenkins, P. Calverley, J. Anderson, G. Ferguson, P. Jones, J. Vestbo, J. Yates, B. Celli (Sydney, Australia; Liverpool, Greenford, London, Manchester, United Kingdom; Livonia, MI, RTP, NC, Boston, MA, United States Of America)
|  |
Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study V. Schelfhout, G. Joos, E. Garcia Gil, E. Massana Montejo (Ghent, Belgium; Barcelona, Spain)
|   |
Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD P. Santus, A. D‘Adda, S. Pizzolato, F. Di Marco, S. Centanni, M. Cazzola (Milan, Rome, Italy)
|  |
Endurance shuttle walking test: response to salmeterol in chronic obstructive pulmonary disease C. Brouillard, V. Pepin, J. Milot, Y. Lacasse, F. Maltais (Quebec, QC, Montreal, QC, Canada)
|   |
Tiotropium (T) and fluticasone/salmeterol combination (FSC) do not cause oxygen desaturation in COPD F. Andò, P. Ruggeri, G. Girbino, M. Cazzola (Messina, Rome, Italy)
|  |
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, L. Brookman (Horsham, United Kingdom; East Hanover, CA, United States Of America; Basel, Switzerland)
|  |